�Bavarian Nordic's US subsidiary company, BN ImmunoTherapeutics has entered into a scientific partnership with the National Cancer Institute (NCI) in the United States. Under the Cooperative Research and Development Agreement (CRADA) the NCI and Bavarian Nordic will jointly develop new immunotherapies for the treatment of prostate cancer. Under the CRADA, BN ImmunoTherapeutics has rights to exclusively licence intellectual attribute that results from this collaboration.
Bavarian Nordic testament in the future explore opportunities for extending this collaboration to further develop its cancer projects. By combining Bavarian Nordic's expertness within cancer vaccine development with one of the world's starring centres of excellence inside cancer research, the company is confident that this collaboration will result in new and innovative solutions to a disease orbit with high gear unmet medical needs as well as expand and accelerate Bavarian Nordic's cancer the Crab activities.
Through the quislingism and a license concord with the United States Public Health Service, the company has obtained rights to intellectual property rights covering a prostate cancer vaccine ware candidate in late phase II clinical development. Data from key clinical studies with this vaccine campaigner are currently being evaluated. Later in 2008 the company will inform the market about how this development image will have a future in the pipeline of Bavarian Nordic.
About the NCI
The National Cancer Institute (NCI) is part of the National Institutes of Health (NIH) and is the United States federal government's preeminent cancer inquiry organization.
- The National Cancer Institute (NCI) has played an active role in the development of drugs for cancer handling for over 50 long time. This is reflected in the fact that or so one half of the chemotherapeutic drugs currently used by oncologists for cancer treatment were discovered and/or developed at NCI.
- NCI has supported the research efforts of at least 20 Nobel Prize winners. For approximately half of these Nobel laureates, NCI supported the awarded research.
- According to a 1996 NCI analysis of drugs approved by the FDA, two-thirds of the antitumour drugs approved as of the end of 1995 were NCI-sponsored Investigational New Drugs.
The collaboration with the NCI does non change Bavarian Nordic's antecedently announced financial guidance for 2008.
Anders Hedegaard, President & CEO of Bavarian Nordic, commented:
"I am very happy to see that we are consolidating our firm relationships within the US. The NCI relationship opens up for us new and exciting opportunities inside the force field of cancer and we are proud to join forces with one of the most prestigious and well-established cancer research organisations in the world. In the collaboration with NCI Bavarian Nordic benefits from the tremendous expertise in cancer therapeutics development that is confront in the NCI organization. This will truly strengthen cancer as a strategic focus domain in years to issue forth, in short letter with our outlined strategy."
About Bavarian Nordic
Bavarian Nordic A/S is a leading industrial biotech company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical pauperism. The company's business scheme is focused in three areas: biodefence, cancer and infectious diseases. Bavarian Nordic's proprietary and patented applied science MVA-BN� is one of the world's safest, multivalent vaccine vectors. Bavarian Nordic has ongoing contracts with the US government for the late-stage development and procurement of the company's third-generation variola vaccine, IMVAMUNE�.
Bavarian Nordic is listed on the OMX Nordic Exchange Copenhagen under the symbolization BAVA.
Bavarian Nordic
More info
